Molecular Spectrum of K-RAS Mutations in Colorectal Cancer Patients in Peshawar, Pakistan
Article Sidebar
Main Article Content
Abstract
Background: The global incidence of colorectal cancer (CRC) has surged, presenting a significant health challenge with an annual occurrence of 1.7 million cases. The American Cancer Society reports that KRAS and BRAF mutations contribute to 20-50% of CRC cases. This study addresses the gap in data on KRAS mutations in CRC patients in Peshawar, Pakistan.
Objective: To determine the prevalence and types of KRAS mutations in colorectal cancer patients in Peshawar, Pakistan.
Methods: This retrospective, cross-sectional study was conducted at the Nuclear Medicine, Oncology, and Radiotherapy Institute (NORI) Hospital in Islamabad from April to November 2022. DNA was extracted from formalin-fixed, paraffin-embedded tissue blocks of 58 CRC patients, regardless of age and gender, following informed verbal consent. KRAS mutation testing was performed using the Cobas Z480 Real-time thermal cycler.
Results: Among the 58 CRC patients, 34 (58.6%) were females, and 24 (41.4%) were males. The highest CRC incidence (36.2%) was observed in the 11-25 years age group. KRAS mutations at codons 12 and 13 were found in 18% of cases, with all isolates carrying the G12D mutation. Kaplan-Meier analysis revealed a lower survival probability for patients with codon 12 mutations compared to those with codon 13 mutations.
Conclusion: The study highlights the need for broader research on KRAS mutations across diverse ethnicities and geographical regions in Pakistan to better understand CRC prevalence and improve patient outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Qayyum A, Nagi AH, Murtaza BN, Shakoori AR. Prevalence of Colorectal Adenocarcinoma in Northern Regions of Pakistan: A Cross Sectional Study. Pakistan Journal of Zoology. 2016;48(6).
Abulkair O, Alqahtani A, Gasmelseed A, Abdelhafiz N, Al Olayan A, Saadeddin A. KRAS Mutational Status and its Clinical Implications in Saudi Colorectal Cancer Patients. Pan Arab Journal of Oncology. 2016;9(1).
Hussain M, Waqas O, Hassan U, Loya A, Akhtar N, Mushtaq S, et al. Right-sided and left-sided colon cancers are two distinct disease entities: an analysis of 200 cases in Pakistan. Asian Pac J Cancer Prev. 2016;17(5):2545-8.
Korphaisarn K, Pongpaibul A, Roothumnong E, Pongsuktavorn K, Thamlikitkul L, Anekpuritanang T, et al. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer. Asian Pacific journal of cancer prevention: APJCP. 2019;20(8):2319.
Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Scientific reports. 2015;5(1):1-8.
Kodaz H, Taştekin E, Erdoğan B, Hacıbekiroğlu İ, Tozkır H, Gürkan H, et al. KRAS mutation in small cell lung carcinoma and extrapulmonary small cell cancer. Balkan medical journal. 2016;33(4):407.
Zekri J, Karim SM, Al-Shehri A, Mahrous M, Darwish T, El Taani H. Frequency and clinical impact of KRAS mutations in patients with colorectal cancer from the middle east. Journal of Analytical Oncology. 2016;5(2):67-74.
Awidi M, Ababneh N, Shomaf M, Al Fararjeh F, Owaidi L, AlKhatib M, et al. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. Plos one. 2019;14(12):e0226473.
Patel L, Wolter-Warmerdam K, Leifer N, Hickey F. Behavioral characteristics of individuals with Down syndrome. Journal of Mental Health Research in Intellectual Disabilities. 2018;11(3):221-46.
Omidifar NM, Geramizadeh BM, Mirzai MM. K-ras Mutation in Colorectal Cancer, A Report from Southern Iran. Iranian journal of medical sciences. 2015;40(5):454-60.
Foltran L, Maglio GD, Pella N, Ermacora P, Aprile G, Masiero E, et al. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncology. 2015;11(4):629-40.
Omidifar N, Geramizadeh B, Mirzai M. K-ras mutation in colorectal cancer, a report from Southern Iran. Iranian journal of medical sciences. 2015;40(5):454.
Tunio MA, Rafi M, Qayyum A, Hashmi A. Present and Future of Radiotherapy in Pakistan. Pakistan Journal of Medical Research. 2010;49(4):81.
Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews. 2020 Dec;39(4):1029-38.
Ounissi D, Weslati M, Boughriba R, Hazgui M, Bouraoui S. Clinicopathological characteristics and mutational profile of KRAS and NRAS inTunisian patients with sporadic colorectal cancer. Turkish Journal of Medical Sciences. 2021;51(1):148-58.
Cefalì M, Epistolio S, Palmarocchi MC, Frattini M, De Dosso S. Research progress on KRAS mutations in colorectal cancer. J. Cancer Metastasis Treat. 2021;7:26.
Mosaferi Z, Pirestani M, Arefian E, Gojani G, Kavousinasab N, Karimi P, Deilami A, Abrehdari-Tafreshi Z. Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients. Journal of Gastrointestinal Cancer. 2024 May 6:1-0.
Jasar D, Filipovski V, Kubelka-Sabit K. Clinicopathological and histomorphological association in K-ras mutated colorectal cancer. Virchows Archiv. 2022(481):1-364.
Rasool M, Pushparaj PN, Buhmeida A, Karim S. Mutational spectrum of BRAF gene in colorectal cancer patients in Saudi Arabia. Saudi Journal of Biological Sciences. 2021 Oct 1;28(10):5906-12.
László L, Kurilla A, Takács T, Kudlik G, Koprivanacz K, Buday L, Vas V. Recent updates on the significance of KRAS mutations in colorectal cancer biology. Cells. 2021 Mar 17;10(3):667.